You are leaving Medscape Education
Cancel Continue
Log in to save activities Your saved activities will show here so that you can easily access them whenever you're ready. Log in here CME & Education Log in to keep track of your credits.
 

CME / ABIM MOC

Harnessing the Potential of Advanced Prostate Cancer Therapies: Maximizing Clinical Benefits for Patients

  • Authors: Neal Shore, MD, FACS; Amit Bahl, MD, FRCR, FRCP; Laura-Maria Krabbe, MD; Aurelius Omlin, MD
  • CME / ABIM MOC Released: 3/29/2023
  • Valid for credit through: 3/29/2024, 11:59 PM EST
Start Activity

  • Credits Available

    Physicians - maximum of 1.00 AMA PRA Category 1 Credit(s)™

    ABIM Diplomates - maximum of 1.00 ABIM MOC points

    You Are Eligible For

    • Letter of Completion
    • ABIM MOC points

Target Audience and Goal Statement

This educational activity is intended for an international audience of non-US oncologists, urologists, radiologists, pharmacists, oncology nurses, and other members of the oncology care team actively treating and managing patients with advanced prostate cancer.

The goal of this activity is for learners to be better able to understand the clinical context of the latest data on the management of advanced prostate cancer, and how to apply this in clinical practice to individualize care based upon patient characteristics. A review of the ongoing challenges in the care of patients with advanced prostate cancer will also be included in this activity.

Upon completion of this activity, participants will:

  • Have increased knowledge regarding the
    • Clinical data for androgen receptor-targeting agents in advanced prostate cancer
    • Ongoing challenges in the management of patients with advanced prostate cancer
  • Have greater competence related to
    • Aligning treatment to the individual with advanced prostate cancer based upon patient characteristics
  • Demonstrate greater confidence in their ability to
    • Provide the appropriate care to patients with advanced prostate cancer based upon all clinical and patient factors


Disclosures

Medscape, LLC requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

All relevant financial relationships for anyone with the ability to control the content of this educational activity are listed below and have been mitigated. Others involved in the planning of this activity have no relevant financial relationships.

Disclosures for additional planners can be found here.


Faculty

  • Neal Shore, MD, FACS

    CMO, Urology/Surgical Oncology
    GenesisCare
    Medical Director
    Carolina Urologic Research Center
    Myrtle Beach, South Carolina, United States

    Disclosures

    Neal Shore, MD, FACS, has the following relevant financial relationships:
    Consultant or advisor for: AbbVie Inc.; Alessa; Arquer; Astellas Pharma, Inc.; AstraZeneca; Bayer HealthCare; Bristol Myers Squibb Company; Clarity; Cold Genesys; Dendreon Corporation; Ferring Pharmaceuticals; Foundation Medicine, Inc.; ImmunityBioIncyte; Invitae Corporation; Janssen Pharmaceuticals; Lantheus Medical Imaging; Lilly; Merck & Co., Inc.; Minomic; Myovant Sciences Ltd.; Myriad; NGM Biopharmaceuticals; Nonagen; Novartis Pharmaceuticals; Pfizer, Inc.; Photocure ASA; Promaxo; Protara; Sanofi; SesenBio; Telix; Tolmar; Vaxiion
    Speaker or member of speakers bureau for: Astellas Pharma, Inc.; Bayer HealthCare; Janssen Pharmaceuticals; Pfizer, Inc.
    Research funding from: AbbVie, Inc.; Alessa; Arquer; Astellas Pharma, Inc.; AstraZeneca; Bayer HealthCare; Bristol Myers Squibb Company; Clarity; Cold Genesys; Dendreon Corporation; Ferring Pharmaceuticals; Foundation Medicine, Inc.; ImmunityBioIncyte; Invitae Corporation; Janssen Pharmaceuticals; Lantheus Medical Imaging; Lilly; Merck & Co., Inc.; Minomic; Myovant Sciences Ltd.; Myriad; NGM Biopharmaceuticals; Nonagen; Novartis Pharmaceuticals; Pfizer, Inc.; Photocure ASA; Promaxo; Protara; Sanofi; SesenBio; Telix; Tolmar; Vaxiion
    Contracted researcher for: AbbVie, Inc.; Alessa; Arquer; Astellas Pharma, Inc.; AstraZeneca; Bayer HealthCare; Bristol Myers Squibb Company; Clarity; Cold Genesys; Dendreon Corporation; Ferring Pharmaceuticals; Foundation Medicine, Inc.; ImmunityBioIncyte; Invitae Corporation; Janssen Pharmaceuticals; Lantheus Medical Imaging; Lilly; Merck & Co., Inc.; Minomic; Myovant Sciences Ltd.; Myriad; NGM Biopharmaceuticals; Nonagen; Novartis Pharmaceuticals; Pfizer, Inc.; Photocure ASA; Promaxo; Protara; Sanofi; SesenBio; Telix; Tolmar; Vaxiion
    Stock options from: Alessa; Photocure ASA; Promaxo

  • Amit Bahl, MD, FRCR, FRCP

    Consultant Oncologist
    University Hospitals Bristol
    Bristol, United Kingdom

    Disclosures

    Amit Bahl, MD, FRCR, FRCP, has the following relevant financial relationships:
    Consultant or advisor for: AAA Pharma; Astellas Pharma, Inc.; Bayer HealthCare; Janssen Pharmaceuticals
    Speaker or member of speakers bureau for: AAA Pharma; Astellas Pharma, Inc.; Bayer HealthCare; Bristol Myers Squibb Company; Eisai, Inc.; Ipsen; Janssen Pharmaceuticals; Novartis Pharmaceuticals
    Research funding from: Bayer HealthCare; Janssen Pharmaceuticals; Sanofi

  • Laura-Maria Krabbe, MD

    Professor of Urology
    University of Münster Medical Center
    Münster, Germany

    Disclosures

    Laura-Maria Krabbe, MD, has the following relevant financial relationships:
    Consultant or advisor for: Amgen, Inc.; Astellas Pharma, Inc.; AstraZeneca; Bayer HealthCare; Bristol Myers Squibb Company; Janssen Pharmaceuticals; Merck & Co., Inc.; Merck Sharp & Dohme GmbH; Novartis Pharmaceuticals; Pfizer, Inc.; Roche
    Speaker or member of speakers bureau for: Amgen, Inc.; Astellas Pharma, Inc.; AstraZeneca; Bayer HealthCare; Bristol Myers Squibb Company; Janssen Pharmaceuticals; Merck Sharp & Dohme GmbH; Pfizer, Inc.; Roche; Recordati

  • Aurelius Omlin, MD

    Onkozentrum Zürich
    University of Zürich and Tumorzentrum Hirslanden Klinik Zürich
    Zürich, Switzerland

    Disclosures

    Aurelius Omlin, MD, has the following relevant financial relationships:
    Consultant or advisor for: Astellas Pharma, Inc.; AstraZeneca; Bayer HealthCare; Janssen Pharmaceuticals; Molecular Partners A.G.; Merck & Co., Inc.; Merck Sharp & Dohme GmbH; Myriad; Novartis Pharmaceuticals; Pfizer, Inc.; Roche; Sanofi-Aventis
    Speaker or member of speakers bureau for: Astellas Pharma, Inc.; AstraZeneca; Bayer HealthCare; Janssen Pharmaceuticals
    Research funding from: Janssen Oncology; Teva Pharmaceutical Industries Ltd.

Editor

  • Deborah Grainger, PhD

    Medical Education Director, WebMD Global, LLC

    Disclosures

    Deborah Grainger, PhD, has no relevant financial relationships.

Compliance Reviewer

  • Leigh Schmidt, MSN, RN, CNE, CHCP

    Associate Director, Accreditation and Compliance, Medscape, LLC

    Disclosures

    Leigh Schmidt, MSN, RN, CNE, CHCP, has no relevant financial relationships.

Peer Reviewer

This activity has been peer reviewed and the reviewer has no relevant financial relationships.


Accreditation Statements

Medscape

Interprofessional Continuing Education

In support of improving patient care, Medscape, LLC is jointly accredited with commendation by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

    For Physicians

  • Medscape, LLC designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™ . Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. Aggregate participant data will be shared with commercial supporters of this activity.

    The European Union of Medical Specialists (UEMS)-European Accreditation Council for Continuing Medical Education (EACCME) has an agreement of mutual recognition of continuing medical education (CME) credit with the American Medical Association (AMA). European physicians interested in converting AMA PRA Category 1 credit™ into European CME credit (ECMEC) should contact the UEMS (www.uems.eu).

    College of Family Physicians of Canada Mainpro+® participants may claim certified credits for any AMA PRA Category 1 credit(s)™, up to a maximum of 50 credits per five-year cycle. Any additional credits are eligible as non-certified credits. College of Family Physicians of Canada (CFPC) members must log into Mainpro+® to claim this activity.

    Contact This Provider

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]


Instructions for Participation and Credit

There are no fees for participating in or receiving credit for this online educational activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the activity online during the valid credit period that is noted on the title page. To receive AMA PRA Category 1 Credit™, you must receive a minimum score of 75% on the post-test.

Follow these steps to earn CME/CE credit*:

  1. Read the target audience, learning objectives, and author disclosures.
  2. Study the educational content online or printed out.
  3. Online, choose the best answer to each test question. To receive a certificate, you must receive a passing score as designated at the top of the test. We encourage you to complete the Activity Evaluation to provide feedback for future programming.

You may now view or print the certificate from your CME/CE Tracker. You may print the certificate but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period you can print out the tally as well as the certificates from the CME/CE Tracker.

*The credit that you receive is based on your user profile.

CME / ABIM MOC

Harnessing the Potential of Advanced Prostate Cancer Therapies: Maximizing Clinical Benefits for Patients

Authors: Neal Shore, MD, FACS; Amit Bahl, MD, FRCR, FRCP; Laura-Maria Krabbe, MD; Aurelius Omlin, MDFaculty and Disclosures

CME / ABIM MOC Released: 3/29/2023

Valid for credit through: 3/29/2024, 11:59 PM EST

processing....

Learning Feedback Questions

Please answer these questions to complement your learning experience.

  • Print